The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 41)
Improved Biomarkers & Clinical Outcome Measures, 2017
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time and lets it "leak" into the brain when needed. This levodopa reservoir appears to get "leakier" as PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we...
Researchers: Kevin J. Black, MD
PPMI Data Challenge, 2016
As Parkinson's disease (PD) is highly heterogeneous, identifying coherent PD subtypes is crucial for understanding the underlying mechanism of the disease and designing and testing appropriate therapies. Existing studies mostly focus on discovering static patterns among PD patients with vector-based models. However, the disease progression patterns of PD patients could also be very...
Research Grant, 2016
Biomarkers (markers of disease activity) are needed to help determine a diagnosis of Parkinson's disease (PD) and to monitor disease progression. Reduced cerebrospinal fluid (baths the brain and spinal cord; CSF) levels of the alpha-synuclein protein is the most consistent potential PD biomarker to date; however, obtaining CSF samples is not always practical. Therefore, the Zhang ...
Researchers: Jing Zhang, MD, PhD
Research Grant, 2014
mGluR3 is a protein and target for neuroprotection. We have recently demonstrated that selective mGluR3 positive allosteric modulators (PAMs) mimic neuroprotective effects and production of neurotrophic factors (proteins that grow and protect neurons) induced by mGluR3 activation. The goals of the current project are to nominate an mGluR3 PAM candidate for pre-clini...
Researchers: Stephan Schann, PhD
Rapid Response Innovation Awards, 2014
Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option. We have compelling evidence that chemical compounds called tricyclics (primarily used as antidepressants) significantly reduce alpha-synuclein aggregation in a new Parkinson's disease model. This pr...